



Supplementary Figure. S3. Effects of MEK1 P124S co-expression with B-RAF V600K on cellular p-ERK levels and growth inhibitory sensitivities to B-RAF_i and MEK_i. (A) The YULAC^{V600K}B-RAF melanoma cell line was stably introduced with the doxycycline-repressible tetracycline transactivator (tTA) and subsequently with vector, FLAG-MEK1, or FLAG-MEK1 P124S expression constructs. Stable cell lines incubated with doxycycline (100 ng/ml) or washed from doxycycline for 2 days were lysed, and the lysates probed for levels of indicated proteins by Western blotting. Tubulin, loading controls. (B) Survival curves for indicated YULAC stable cell lines treated with the indicated [PLX4032] or [AZD6244] for 72 h in the presence of doxycycline (top) or its absence (bottom). Data represent percent surviving cells relative to DMSO-treated controls (mean ± SEM, n = 5). The dashed line corresponds to 50% cell killing.